News & Press

Abbisko Therapeutics Featured at the 39th Annual J.P. Morgan Healthcare Conference

Jan 19,2021
By Abbisko
Back

图片1.png

January 19, 2021, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter),  a clinical stage biopharmaceutical company focused on discovering and developing innovative molecularly-targeted and immuno-oncology therapies, today announced that Dr. Yao-Chang XU, Chairman and CEO of the company, has attended the 39th Annual JP Morgan Healthcare Conference. Dr. Xu delivered a presentation outlining the company’s recent progresses and carried out in-depth discussions with top-tier investors and potential partners together with Abbisko’s management team. Due to the COVID-19 pandemic, the conference was held in an entirely digital format from January 11th to 14th.

J.P. Morgan Annual Healthcare Conference is regarded as one of the most prominent forums for the global healthcare sector, sharing insights on emerging industry and investment trends. The 39th annual conference gathered approximately 600 leading healthcare companies from the world, ranging from emerging private companies to Fortune 100 corporations along with more than 3,000 global investors. Multinational pharmaceutical giants such as Pfizer, Novartis, Bristol Myers Squibb, and others attended as usual. Together with Abbisko, other China-based innovative biomedical companies such as BeiGene, Zai Lab, also participated in the conference.

Dr. Yao-Chang Xu said, “We are delighted to be invited by J.P. Morgan and share our updates with fellow companies and investors in the healthcare industry. Despite the disruptive impacts of COVID-19, Abbisko was able to maintain a brisk pace in development and achieved many milestones in the past year. We have advanced four programs into clinical development with seven IND approvals already obtained in different regions of the world. Based on these achievements, we successfully completed the Series C and Series D financing within one year, with the total capital raised to date adding up to $263 million. Our next step is to continue advancing the clinical programs and preclinical pipelines to help solve the unmet medical needs in China and around the world.”

A webcast recording of Abbisko’s presentation is available at https://jpmorgan.metameetings.net/events/healthcare21/sessions/35770-abbisko-therapeutics.

Tel:(+86) 021-68912098

E-Mail:Public@abbisko.com Bd@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1